KMT2A and acute myeloid leukemia: To extend the approach on primary material, we compared our primary MLL-AF9 AML samples with publicly available primary CD14 + monocytes, and vice versa (Fig. 5c, Supplementary Fig. S3f,g,h,i and Supplementary Table S1).